CLEO Diagnostics Ltd (AU:COV) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Cleo Diagnostics Ltd is expanding its ovarian cancer trial with the inclusion of Siles Health, a leading women’s health specialist network in Australia. This collaboration aims to enhance clinical insights and support market adoption of CLEO’s innovative blood test for early ovarian cancer detection. By integrating Siles Health’s expertise, CLEO is poised to advance its trial strategy and increase market awareness for its potentially life-saving diagnostic tool.
For further insights into AU:COV stock, check out TipRanks’ Stock Analysis page.